Mattern MR - Search Results

1

Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.

Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB. Chaturvedi P, et al. Among authors: mattern mr. Oncogene. 1999 Jul 15;18(28):4047-54. doi: 10.1038/sj.onc.1202925. Oncogene. 1999. PMID: 10435585

2

Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity.

Zhou BB, Chaturvedi P, Spring K, Scott SP, Johanson RA, Mishra R, Mattern MR, Winkler JD, Khanna KK. Zhou BB, et al. Among authors: mattern mr. J Biol Chem. 2000 Apr 7;275(14):10342-8. doi: 10.1074/jbc.275.14.10342. J Biol Chem. 2000. PMID: 10744722 Free article.

3

Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity.

Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, Zhou BB. Chaturvedi P, et al. Among authors: mattern mr. Cancer Res. 2002 Mar 15;62(6):1797-801. Cancer Res. 2002. PMID: 11912157

4

Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).

Mattern MR, Hofmann GA, McCabe FL, Johnson RK. Mattern MR, et al. Cancer Res. 1991 Nov 1;51(21):5813-6. Cancer Res. 1991. PMID: 1657371

5

Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.

Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK. Woessner RD, et al. Among authors: mattern mr. Oncol Res. 1992;4(11-12):481-8. Oncol Res. 1992. PMID: 1338578

6

Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.

Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Woessner RD, et al. Among authors: mattern mr. Cell Growth Differ. 1991 Apr;2(4):209-14. Cell Growth Differ. 1991. PMID: 1651102

7

Regulation of topoisomerase I and II activities by cyclic nucleotide- and phospholipid-dependent protein kinases. Effects of interactions between the two transduction pathways.

Mattern MR, Nambi P, Bartus JO, Mirabelli CK, Crooke ST, Johnson RK. Mattern MR, et al. Receptor. 1991;1(3):181-90. Receptor. 1991. PMID: 1668830

8

Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.

Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK. Eng WK, et al. Among authors: mattern mr. Mol Pharmacol. 1990 Oct;38(4):471-80. Mol Pharmacol. 1990. PMID: 2172765

9

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Tan KB, et al. Among authors: mattern mr. J Natl Cancer Inst. 1989 Nov 15;81(22):1732-5. doi: 10.1093/jnci/81.22.1732. J Natl Cancer Inst. 1989. PMID: 2553992

10

In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.

Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK. Mattern MR, et al. Oncol Res. 1993;5(12):467-74. Oncol Res. 1993. PMID: 8086668

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters